Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1981 1
1983 1
1986 1
1988 1
1990 1
1992 1
1993 1
1999 1
2000 2
2002 6
2003 3
2004 5
2005 8
2006 13
2007 4
2008 12
2009 13
2010 5
2011 11
2012 21
2013 22
2014 24
2015 18
2016 32
2017 46
2018 33
2019 44
2020 47
2021 87
2022 102
2023 86
2024 34

Text availability

Article attribute

Article type

Publication date

Search Results

619 results

Results by year

Filters applied: . Clear all
Page 1
Showing results for interpret kaur
Search for anterpreet kaur instead (2 results)
Functions of Thrombospondin-1 in the Tumor Microenvironment.
Kaur S, Bronson SM, Pal-Nath D, Miller TW, Soto-Pantoja DR, Roberts DD. Kaur S, et al. Int J Mol Sci. 2021 Apr 27;22(9):4570. doi: 10.3390/ijms22094570. Int J Mol Sci. 2021. PMID: 33925464 Free PMC article. Review.
Effectiveness of different treatments for odontogenic keratocyst: a network meta-analysis.
Al-Moraissi EA, Kaur A, Gomez RS, Ellis E 3rd. Al-Moraissi EA, et al. Int J Oral Maxillofac Surg. 2023 Jan;52(1):32-43. doi: 10.1016/j.ijom.2022.09.004. Epub 2022 Sep 21. Int J Oral Maxillofac Surg. 2023. PMID: 36150944 Review.
As this NMA included retrospective studies, the results should be interpreted with great caution (level of evidence: type III)....
As this NMA included retrospective studies, the results should be interpreted with great caution (level of evidence: type III)....
CARD 2023: expanded curation, support for machine learning, and resistome prediction at the Comprehensive Antibiotic Resistance Database.
Alcock BP, Huynh W, Chalil R, Smith KW, Raphenya AR, Wlodarski MA, Edalatmand A, Petkau A, Syed SA, Tsang KK, Baker SJC, Dave M, McCarthy MC, Mukiri KM, Nasir JA, Golbon B, Imtiaz H, Jiang X, Kaur K, Kwong M, Liang ZC, Niu KC, Shan P, Yang JYJ, Gray KL, Hoad GR, Jia B, Bhando T, Carfrae LA, Farha MA, French S, Gordzevich R, Rachwalski K, Tu MM, Bordeleau E, Dooley D, Griffiths E, Zubyk HL, Brown ED, Maguire F, Beiko RG, Hsiao WWL, Brinkman FSL, Van Domselaar G, McArthur AG. Alcock BP, et al. Nucleic Acids Res. 2023 Jan 6;51(D1):D690-D699. doi: 10.1093/nar/gkac920. Nucleic Acids Res. 2023. PMID: 36263822 Free PMC article.
The Comprehensive Antibiotic Resistance Database (CARD; card.mcmaster.ca) combines the Antibiotic Resistance Ontology (ARO) with curated AMR gene (ARG) sequences and resistance-conferring mutations to provide an informatics framework for annotation and interpretation of re …
The Comprehensive Antibiotic Resistance Database (CARD; card.mcmaster.ca) combines the Antibiotic Resistance Ontology (ARO) with curated AMR …
Effect of Amoxicillin Dose and Treatment Duration on the Need for Antibiotic Re-treatment in Children With Community-Acquired Pneumonia: The CAP-IT Randomized Clinical Trial.
Bielicki JA, Stöhr W, Barratt S, Dunn D, Naufal N, Roland D, Sturgeon K, Finn A, Rodriguez-Ruiz JP, Malhotra-Kumar S, Powell C, Faust SN, Alcock AE, Hall D, Robinson G, Hawcutt DB, Lyttle MD, Gibb DM, Sharland M; PERUKI, GAPRUKI, and the CAP-IT Trial Group. Bielicki JA, et al. JAMA. 2021 Nov 2;326(17):1713-1724. doi: 10.1001/jama.2021.17843. JAMA. 2021. PMID: 34726708 Free PMC article. Clinical Trial.
However, disease severity, treatment setting, prior antibiotics received, and acceptability of the noninferiority margin require consideration when interpreting the findings. TRIAL REGISTRATION: ISRCTN Identifier: ISRCTN76888927....
However, disease severity, treatment setting, prior antibiotics received, and acceptability of the noninferiority margin require considerati …
Best practices of formal new graduate transition programs: An integrative review.
Rush KL, Janke R, Duchscher JE, Phillips R, Kaur S. Rush KL, et al. Int J Nurs Stud. 2019 Jun;94:139-158. doi: 10.1016/j.ijnurstu.2019.02.010. Epub 2019 Feb 26. Int J Nurs Stud. 2019. PMID: 30965203 Review.
REVIEW METHODS: Cooper's (1989) five-stage approach to integrative review guided the process: problem formulation, data collection, evaluation of data points, data analysis and interpretation, presentation of results. This approach was supplemented by the PRISMA guidelines …
REVIEW METHODS: Cooper's (1989) five-stage approach to integrative review guided the process: problem formulation, data collection, evaluati …
Thromboelastography (TEG).
Othman M, Kaur H. Othman M, et al. Methods Mol Biol. 2017;1646:533-543. doi: 10.1007/978-1-4939-7196-1_39. Methods Mol Biol. 2017. PMID: 28804853 Review.
In this chapter, we very briefly review TEG applications and discuss interpretations, normal ranges, and reference controls, and we explain the method of TEG run using standard citrated native blood samples. ...We discuss precautions and issues related to the assay, which …
In this chapter, we very briefly review TEG applications and discuss interpretations, normal ranges, and reference controls, and we e …
Evaluation of the oral corticosteroid-sparing effect of tezepelumab in adults with oral corticosteroid-dependent asthma (SOURCE): a randomised, placebo-controlled, phase 3 study.
Wechsler ME, Menzies-Gow A, Brightling CE, Kuna P, Korn S, Welte T, Griffiths JM, Sałapa K, Hellqvist Å, Almqvist G, Lal H, Kaur P, Skärby T, Colice G; SOURCE study group. Wechsler ME, et al. Lancet Respir Med. 2022 Jul;10(7):650-660. doi: 10.1016/S2213-2600(21)00537-3. Epub 2022 Mar 29. Lancet Respir Med. 2022. PMID: 35364018 Clinical Trial.
Serious adverse events were reported in 12 (16%) participants in the tezepelumab group and 16 (21%) participants in the placebo group. INTERPRETATION: We did not observe a significant improvement in oral corticosteroid dose reduction with tezepelumab versus placebo in the …
Serious adverse events were reported in 12 (16%) participants in the tezepelumab group and 16 (21%) participants in the placebo group. IN …
Automated achromatic perimetry.
Aggarwal A, Chhabra K, Kaur P, Singh K, Khosa I, Bansal P. Aggarwal A, et al. Oman J Ophthalmol. 2018 Jan-Apr;11(1):3-10. doi: 10.4103/ojo.OJO_28_2017. Oman J Ophthalmol. 2018. PMID: 29563687 Free PMC article. Review.
This article is an attempt to familiarize the reader with components of an achromatic (white on white) automated perimetry printout. It addresses use of Humphrey perimeter to interpret the results. For the purpose of this review, a PubMed search was made using perimetry, H …
This article is an attempt to familiarize the reader with components of an achromatic (white on white) automated perimetry printout. It addr …
Metabolic non-communicable disease health report of India: the ICMR-INDIAB national cross-sectional study (ICMR-INDIAB-17).
Anjana RM, Unnikrishnan R, Deepa M, Pradeepa R, Tandon N, Das AK, Joshi S, Bajaj S, Jabbar PK, Das HK, Kumar A, Dhandhania VK, Bhansali A, Rao PV, Desai A, Kalra S, Gupta A, Lakshmy R, Madhu SV, Elangovan N, Chowdhury S, Venkatesan U, Subashini R, Kaur T, Dhaliwal RS, Mohan V; ICMR-INDIAB Collaborative Study Group. Anjana RM, et al. Lancet Diabetes Endocrinol. 2023 Jul;11(7):474-489. doi: 10.1016/S2213-8587(23)00119-5. Epub 2023 Jun 7. Lancet Diabetes Endocrinol. 2023. PMID: 37301218
In many states with a lower human development index, the ratio of diabetes to prediabetes was less than 1. INTERPRETATION: The prevalence of diabetes and other metabolic NCDs in India is considerably higher than previously estimated. ...
In many states with a lower human development index, the ratio of diabetes to prediabetes was less than 1. INTERPRETATION: The preval …
Tenecteplase versus alteplase for management of acute ischaemic stroke (NOR-TEST): a phase 3, randomised, open-label, blinded endpoint trial.
Logallo N, Novotny V, Assmus J, Kvistad CE, Alteheld L, Rønning OM, Thommessen B, Amthor KF, Ihle-Hansen H, Kurz M, Tobro H, Kaur K, Stankiewicz M, Carlsson M, Morsund Å, Idicula T, Aamodt AH, Lund C, Næss H, Waje-Andreassen U, Thomassen L. Logallo N, et al. Lancet Neurol. 2017 Oct;16(10):781-788. doi: 10.1016/S1474-4422(17)30253-3. Epub 2017 Aug 2. Lancet Neurol. 2017. PMID: 28780236 Clinical Trial.
The frequency of serious adverse events was similar between groups (145 [26%] in the tenecteplase group vs 141 [26%] in the alteplase group; p=0.74). INTERPRETATION: Tenecteplase was not superior to alteplase and showed a similar safety profile. ...
The frequency of serious adverse events was similar between groups (145 [26%] in the tenecteplase group vs 141 [26%] in the alteplase group; …
619 results